West Announces Third-Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
West Pharma (WST) Tops Q3 EPS by 8c, Revenues Beat; Raises FY19 EPS/Revenue Guidance Above Consensus
October 24, 2019 6:15 AM EDTWest Pharma (NYSE: WST) reported Q3 EPS of $0.79, $0.08 better than the analyst estimate of $0.71. Revenue for the quarter came in at $456.1 million versus the consensus estimate of $450.94 million.
Third-Quarter 2019 Summary (comparisons to prior-year period)
Net sales of $456.1 million grew 5.7%; organic sales growth was 7.9%; sales from a recent acquisition contributed an additional 20 basis points of growth; currency translation reduced sales by 240 basis points.Reported-diluted EPS of $0.75 increased 3%.Adjusted-diluted EPS of $0.79 increased 4%.Company is raising its full-year 2019 net sales guidance to a new range of between $1.815 billion and $1.825... More